

# **CDTI GRANTS**

• IDI-20221002

TITLE OF THE PROJECT

"IKERTU: GENE EXCHANGE SYSTEM WITH BIOTECHNOLOGICAL AND CLINICAL

APPLICATIONS BASED ON LENTISOME".

**SUMMARY OF THE PROJECT** 

VIVEbiotech is a Spanish biotechnological company, CDMO (Contract Development and Manufacturing Organization) that develops and produces lentiviral vectors for gene therapy clinical trials. Located in San Sebastian, it operates in an international market and has a

patented technology (LentiSoma).

The aim of the IKERTU project is to generate a cellular gene therapy platform, based on an episomal gene exchange system (based on LentiSoma) for allogeneic and universal treatment of solid and liquid tumors (IKERTU Platform - Isogenic cells based on Knock in-out gene Exchange

between an acceptoR and Transfer Units).

In this proposal, VIVEbiotech enters into an ambitious and revolutionary project, which will optimize this integrative system, due to the characteristics of the LentiSomas, providing it with control and safety features that differentiate it from the current proposals existing in the market.

We guarantee respect for the environment and equality policies.



## IDI-20230766

#### **TITLE OF THE PROJECT**

### LENTIPURE: "PARADIGM SHIFT IN THE VECTOR PURIFICATION PROCESS LENTIVIRALS"

#### **SUMMARY OF THE PROJECT**

Gene therapy represents an innovative strategy for the treatment of various diseases, using, among others, lentiviral vectors (LVV) for the delivery of therapeutic genes into the patient's body. Due to the rise of these types of therapies in recent years, it is critical to develop a manufacturing process for LVVs that satisfies the market demand in terms of process effectiveness and improved quality of the lentiviral vectors produced. To this end, VIVEbiotech is embarking on an ambitious and revolutionary project that seeks to modify the purification stage of the LVV production process in order to increase the yield and decrease the number of contaminants present in the final product, as well as the development of new analytics that will allow us to better characterize the sample.